ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
65,018.24
-2.21%
S&P 500
5,473.23
0.00%
Dow Jones
38,778.10
0.00%
US Dollar vs Yen
157.761
0.04%
Brent Oil
83.715
-0.22%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NYSE
  6. Amneal Pharmaceuticals Holding Co (AMRX)

  7. Amneal Pharmaceuticals Holding Co (AMRX) ニュース

AMRX

Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals Holding Co
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NYSE:AMRX
日付受信時刻ニュースソース見出しコード企業名
2024/06/0521 : 00Business WireAmneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New TherapiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/2305 : 05Business WireAmneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of CaliforniaNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/2305 : 05Business WireAmneal to Participate at Upcoming Investor ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/1704 : 13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/1704 : 13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/1505 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/1505 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/1505 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/1505 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/0805 : 18Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/0706 : 35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/0706 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/0706 : 28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/0706 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/0706 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/0319 : 14Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/05/0319 : 00Business WireAmneal Reports First Quarter 2024 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/04/2421 : 00Business WireAmneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid OverdoseNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/04/1621 : 00Business WireAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable MedicineNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/04/1021 : 00Business WireAmneal to Report First Quarter 2024 Results on May 3, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/2905 : 05Business WireAmneal to Ring the Nasdaq Closing Bell on April 2, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/2605 : 05Business WireAmneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/2221 : 01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/2221 : 01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/0707 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/0707 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/0606 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/0606 : 35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/0120 : 13Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
2024/03/0120 : 00Business WireAmneal Reports Fourth Quarter and Full Year 2023 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
 Showing the most relevant articles for your search:NYSE:AMRX

最近閲覧した銘柄

NASDAQ
AAZQKXX
Jpmorgan Chase Financial...
COIN
FREERUSD
Ross Ulbricht Genesis Collection
TSXV
TAJ
Tajiri Resources
NASDAQ
VALU
Value Line
BIT
P1R0H7
BNP Paribas Issuance
TSXV
MTB
MTB Metals
BIBX
CRVETH
Curve DAO Token
COIN
BOTSUSD
Deezbots
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有